Recon: Moderna coronavirus vaccine yields immune response in Phase 1 trial; FDA panel backs GSK’s multiple myeloma drug

• Moderna coronavirus vaccine shows promising results in early clinical trial (Politico) (STAT) (Endpoints) (NYTimes) (In the Pipeline) (Financial Times)
• FDA panel votes in favor of approving GSK's multiple myeloma drug (Reuters) (Endpoints)
• J&J's Tremfya Receives FDA Approval for Psoriatic Arthritis (Press)
• Fake pharmaceutical ad urges viewers to ‘take the shot’ (AFP)
• Teva Picked as Bellwether Target in Generic Drug Price-Fix Case (Bloomberg) (Law360)
• Ohio sues Express Scripts for ‘egregiously’ overcharging for medicines (STAT)
• AbbVie uses dozens of patents to ward off competition for a pricey cancer medicine (STAT) (BioPharmaDive)
• Sun Pharma employee says she was fired for complaining that samples were improperly shipped (STAT)

• Key UK Covid Trial to Add Drug to Tests Before Winter Threat (Bloomberg)
• WHO and UNICEF warn of a decline in vaccinations during COVID-19 (WHO)
• A day after Moderna vaccine results, rumors swirl of pending AstraZeneca data (Endpoints) (ITV)
• Drug maker offers to slash prices on cancer medicines to end European price gouging probe (STAT)
• Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads (STAT)
• MilliporeSigma to build new $20 million, 12,000-square-foot lab in Switzerland (Endpoints)
• Orchard licenses gene therapy tech from GSK (Fierce)
• Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate (Economic Times)
• UK Eyeing Conditions On Stryker's $4B Wright Medical Deal (Law360)

• What’s behind the explosive new fight over Covid-19 data (Politico)
• Trump Administration Strips C.D.C. of Control of Coronavirus Data (NYTimes)
• Despite Shortfalls And Delays, U.S. Testing Czar Says Efforts Are Mostly 'Sufficient’ (NPR)
• Baby Was Infected With Coronavirus in Womb, Study Reports (NYTimes)
• FDA Announces Resumption of Domestic Inspections – Will Foreign Inspections Soon Follow? (FDA Law Blog)
• Covid-19 roundup: Vaccine by end of 2020? Ken Frazier warns hype doing 'grave disservice' (Endpoints)
• Drug firms get DGCI nod for Covid drug favipiravir despite inconclusive study (Economic Times)
• Nephron looks to break into COVID-19 vaccine territory with $216M investment (Fierce)
• Ensuring the Safety of Patients in Clinical Trials Studying Investigational New Drugs to Prevent or Treat COVID-19 (FDA)
• Coronavirus (COVID-19) Update: Daily Roundup July 14, 2020 (FDA)

• The Record-Breaking Biotech Funding Tsunami Of 1H2020 (LifeSciVC)
• Re-Wiring US FDA’s Regulatory Thinking (Pink Sheet)
• EMA Presses On With Guidance On Secondary Use Of Health Data (Pink Sheet)
• Clinical Trials: Industry Navigating Alternative Ways Of Delivering Investigational Drugs During Pandemic (Pink Sheet)
• FDA raises questions about Mallinckrodt's HRS-1 drug before advisory hearing (Endpoints)
• Gilead-partnered Glympse snares $46.7M for their NASH-snooping biosensors (Endpoints)
• Preventive studies for Eisai, Biogen Alzheimer's drug could add years to amyloid debate (BioPharmaDive)
• Samsung Biologics May Add Manufacturing Capacity at its Site in Korea (Big Molecule Watch)
• Patients Call For EU-Level Differential Pricing (Pink Sheet)
• Pfizer doubles down on Syneos Health with new services pact (Fierce)
• Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop (Fierce)
• 'Longevity as a service': Insilico spins off AI biotech that trains deep learning on anti-aging treatments (Endpoints)
• Journals endorse new checklist to clean up sloppy animal research (Science Mag)
• The Flu May Linger in the Air, Just Like the Coronavirus (NYTimes)

• ElectroCore noninvasive nerve stimulator gets EUA for COVID-19 patients with asthma (MedtechDive)
• European Commission On Track To Appoint Expert Panel Members By End Of July (MedtechInsight)

• C.D.C. Employees Accuse Agency of ‘Toxic Culture of Racial Aggressions’ (NYTimes)
• Trump administration asks Supreme Court to reinstate Arkansas Medicaid work requirements (The Hill)
• A Few More Words on the D.C. Cir.’s Dumping of the Drug Price Disclosure Rule (Drug & Device Law)